

## 30 September 2019

# Renalytix AI plc ("RenalytixAI" or the "Company")

#### **Result of AGM**

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces at its annual general meeting held earlier today, the following resolutions were passed on a show of hands with the table below summarising proxy votes:

	Resolution	Votes for*	Votes against	Votes withheld
1.	To receive the audited accounts of the Company	24,481,789	22	0
2.	To re-elect Julian Baines	24,481,789	22	0
3.	To re-elect Christopher Mills	20,570,985	3,910,826	0
4.	To re-elect Richard Evans	24,481,789	22	0
5.	To re-elect Fergus Fleming	24,481,789	22	0
6.	To elect Doctor Erik Lium	24,481,789	22	0
7.	To elect James McCullough	24,481,789	22	0
8.	To elect Barbara Murphy	24,481,811	0	0
9.	To re-appoint the auditors PKF Littlejohn LLP and authorise the Directors to fix their remuneration	24,481,789	22	0
10.	To authorise the directors to replace the existing authority to allot shares in the Company in connection with s551 of the Companies Act 2006	24,481,789	22	0
11.	To authorise the directors to allot Relevant Securities as if s561 of the Companies Act 2006 did not apply	23,769,147	702,664	10,000

 $<sup>\</sup>hbox{*Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.}$ 

## For further information, please contact:

Renalytix AI plc

James McCullough, CEO

Www.renalytixai.com
Via Walbrook PR

Tel: 020 7710 7600

Stifel (Nominated Adviser & Joint Broker)
Alex Price / Jonathan Senior / Ben Maddison

N+1 Singer (Joint Broker) Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance) Tom Salvesen / Mia Gardner (Corporate Broking)

Walbrook PR Limited Tel: 020 7933 8780 or <a href="mailto:renalytix@walbrookpr.com">renalytix@walbrookpr.com</a>

### **About Kidney Disease**

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

### About RenalytixAl

RenalytixAl is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit <a href="renalytixai.com">renalytixai.com</a>.